Alphamab Oncology 9966.HK Stock
Alphamab Oncology Price Chart
Alphamab Oncology 9966.HK Financial and Trading Overview
Alphamab Oncology stock price | 4.48 HKD |
Previous Close | 7.51 HKD |
Open | 7.62 HKD |
Bid | 8.2 HKD x N/A |
Ask | 8.22 HKD x N/A |
Day's Range | 7.62 - 8.47 HKD |
52 Week Range | 5.45 - 17.7 HKD |
Volume | 14.43M HKD |
Avg. Volume | 7.16M HKD |
Market Cap | 7.91B HKD |
Beta (5Y Monthly) | 0.782649 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.24 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.79 HKD |
9966.HK Valuation Measures
Enterprise Value | 5.89B HKD |
Trailing P/E | N/A |
Forward P/E | -16.078432 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 47.416393 |
Price/Book (mrq) | 4.945718 |
Enterprise Value/Revenue | 35.317 |
Enterprise Value/EBITDA | -15.039 |
Trading Information
Alphamab Oncology Stock Price History
Beta (5Y Monthly) | 0.782649 |
52-Week Change | -4.81% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17.7 HKD |
52 Week Low | 5.45 HKD |
50-Day Moving Average | 12.35 HKD |
200-Day Moving Average | 10.85 HKD |
9966.HK Share Statistics
Avg. Volume (3 month) | 7.16M HKD |
Avg. Daily Volume (10-Days) | 5.27M HKD |
Shares Outstanding | 964.78M |
Float | 416.97M |
Short Ratio | N/A |
% Held by Insiders | 50.79% |
% Held by Institutions | 16.87% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -195.22% |
Operating Margin (ttm) | -259.14% |
Gross Margin | 73.50% |
EBITDA Margin | -234.84% |
Management Effectiveness
Return on Assets (ttm) | -11.20% |
Return on Equity (ttm) | -19.0039% |
Income Statement
Revenue (ttm) | 166.84M HKD |
Revenue Per Share (ttm) | 0.18 HKD |
Quarterly Revenue Growth (yoy) | -22.40% |
Gross Profit (ttm) | N/A |
EBITDA | -391828992 HKD |
Net Income Avi to Common (ttm) | -325721984 HKD |
Diluted EPS (ttm) | -0.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.35B HKD |
Total Cash Per Share (mrq) | 1.44 HKD |
Total Debt (mrq) | 345.39M HKD |
Total Debt/Equity (mrq) | 22.17 HKD |
Current Ratio (mrq) | 3.883 |
Book Value Per Share (mrq) | 1.658 |
Cash Flow Statement
Operating Cash Flow (ttm) | -300308000 HKD |
Levered Free Cash Flow (ttm) | -332016640 HKD |
Profile of Alphamab Oncology
Country | Hong Kong |
State | N/A |
City | Suzhou |
Address | No. 175 Fangzhou Road |
ZIP | N/A |
Phone | 86 512 6285 0800 |
Website | https://www.alphamabonc.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 472 |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody, which is in phase I clinical trial for the treatment of advanced solid tumors; and JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Alphamab Oncology Stock
What is a current 9966.HK stock price?
Alphamab Oncology 9966.HK stock price today per share is 4.48 HKD.
How to purchase Alphamab Oncology stock?
You can buy 9966.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alphamab Oncology?
The stock symbol or ticker of Alphamab Oncology is 9966.HK.
Which industry does the Alphamab Oncology company belong to?
The Alphamab Oncology industry is Biotechnology.
How many shares does Alphamab Oncology have in circulation?
The max supply of Alphamab Oncology shares is 964.84M.
What is Alphamab Oncology Price to Earnings Ratio (PE Ratio)?
Alphamab Oncology PE Ratio is now.
What was Alphamab Oncology earnings per share over the trailing 12 months (TTM)?
Alphamab Oncology EPS is -0.24 HKD over the trailing 12 months.
Which sector does the Alphamab Oncology company belong to?
The Alphamab Oncology sector is Healthcare.
Alphamab Oncology 9966.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}